AI Guidance for Biopsy in Suspected Cholangiocarcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05374122|
Recruitment Status : Active, not recruiting
First Posted : May 16, 2022
Last Update Posted : March 6, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Digital single-operator cholangioscopy (DSOC) has emerged as a medical advance with an important role in the evaluation of indeterminate biliary lesions. This technique has demonstrated higher sensitivity in the guidance for tissue acquisition when compared with standard endoscopic retrograde cholangiopancreatography (ERCP). DSOC-guided biopsy is considered technically safe and successful for tissue collection.
Hand in hand with the development of more precise diagnostic techniques, comes the implementation of artificial intelligence (AI) for diagnostic assessment. For the past decade, the role of artificial intelligence (AI) has been increasing at a rapid pace. In the biliary tract, different models have been proposed for the characterization of malignant features. Nevertheless, to date, the discrepancy between the visual impression of the operator and the histological results obtained by cholangioscopy still present, affecting the accuracy the diagnosis.
Based on the above, the investigators aim to assess the diagnostic accuracy of AI for the guidance of tissue acquisition with DSOC compared to DSOC without AI for suspected cholangiocarcinoma. As a secondary aim, the investigators pursue to compare quality of AI-guided biopsies samples vs. DSOC biopsies without AI.
|Condition or disease||Intervention/treatment||Phase|
|Neoplasms Non-Neoplastic Bile Duct Neoplasms Bile Duct Lesions||Diagnostic Test: DSOC with AI biopsy guidance Diagnostic Test: DSOC biopsy without AI guidance||Not Applicable|
The diagnosis and management of biliary malignancy currently represents a medical challenge. To date, DSOC has demonstrated high sensitivity in the detection of malignant biliary lesions, nevertheless there is not a universal expert consensus for the characterization of this lesions. Also, DSOC has shown to be safe and successful for specimen collection with higher sensitivity when compared with standard ERCP.
Moreover, most of the AI models proposed for characterization of neoplastic features in biliary lesions have demonstrated high reliability during DSOC performance. A model was the proposed by investigators in Ecuador, focused on the identification of features of malignancy. The detection is performed by surrounding the suspected lesion in a bounding box. The detected area is displayed in the right side of the screen. Also, the box/image of the presumptive lesion can also be recorded and reviewed afterwards. After the AI model detects the "malignant area", a tissue sample is collected and taken for histopathological studies.
In addition, due to a variation of the endoscopists´ intra and interobserver agreement and the discrepancy between the visual impression and histopathological findings, the investigators intend to take advantage of our AI model as a diagnostic tool for a more precise acquisition of tissue in lesions suggestive of malignancy during real-time DSOC.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Randomized controlled trial|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of Artificial Intelligence Aid-digital Single-operator Cholangioscopy (DSOC) Guided-biopsy Sampling in Suspected Cholangiocarcinoma: A Prospective, Randomized Trial|
|Actual Study Start Date :||May 1, 2022|
|Estimated Primary Completion Date :||December 30, 2023|
|Estimated Study Completion Date :||May 1, 2024|
Experimental: DSOC + AI-biopsy guidance
This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy. In this group, the investigators aim to use as a complement tool an AI model for the detection of features suggestive of malignancy to perform the biopsy on the detecting bounding box signal.
A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions.
Diagnostic Test: DSOC with AI biopsy guidance
Patients with a presumptive diagnosis of biliary malignancy will undergo DSOC + Artificial intelligence model (AIWorks) guidance for detection of neoplastic lesion during real-time procedure, tissue sampling acquisition, and histopathological analysis.
Active Comparator: DSOC biopsy without AI guidance
This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy without AI guidance. A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions.
Diagnostic Test: DSOC biopsy without AI guidance
Patients with lesions suggestive of malignancy will undergo DSOC without AI guidance for sampling.
Based on the observer´s criteria regarding areas suggestive of malignancy, the collected tissue sample will be sent for histopathological studies.
- Cholangiocarcinoma diagnosis confirmation after biopsy and six-month follow-up [ Time Frame: Six months ]
To confirm the diagnosis based on pathology results from specimens obtained through DSOC (with or without AI-guided biopsy) or findings from further indicated procedures, including brush cytology fluoroscopy-guided biopsy, endoscopic ultrasound-guided tissue sampling, and surgical samples.
Finally, the gold standard is a six-month follow-up compared against the AI model (group 1) or the DSOC endoscopist experts' classification. The data will be verified through a 2 x 2 contingency table.
- Insufficient biopsy sample rate [ Time Frame: Six months ]Four biopsies will be performed per each case. Rate of insufficient samples by each study group will be recorded and compared.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 99 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients referred to our center with an indication of DSOC due to suspicion of CBD tumor or indeterminate CBD stenosis.
- Patients who authorized for DSOC-guided biopsy.
- Any clinical condition which makes DSOC inviable.
- Patients with more than one DSOC.
- Lost on a six-month follow-up after DSOC.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05374122
|Guayaquil, Guayas, Ecuador, 090505|
|Principal Investigator:||Carlos Robles-Medranda, MD FASGE||Ecuadorian Institute of Digestive Diseases|
|Responsible Party:||Carlos Robles-Medranda, Principal Investigator, Instituto Ecuatoriano de Enfermedades Digestivas|
|Other Study ID Numbers:||
|First Posted:||May 16, 2022 Key Record Dates|
|Last Update Posted:||March 6, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Bile Duct Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases